Search

Displaying results 3251 - 3260 of 5506 in total
  1. Drug

    ARCoV

    go.drugbank.com/drugs/DB15855
    Experimental

    Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. … As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112).

  2. Drug

    Moxifloxacin

    go.drugbank.com/drugs/DB00218
    ApprovedInvestigational

    Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

    Products: MOXIFLOXACINA DOUBLE-E PHARMA, T & B
  3. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. … Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.

  4. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique ...

  5. Drug

    Aluminum zirconium pentachlorohydrex gly

    go.drugbank.com/drugs/DB11277
    ApprovedWithdrawn

    It is a coordination complex of Aluminum Zirconium pentachlorohydrate and glycine. Its anhydrous form allows the molecule to absorb moisture.

  6. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  8. Drug

    Belladonna

    go.drugbank.com/drugs/DB13913
    Approved

    Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family Solanaceae. Its roots, leaves and fruits contain DB00424, DB00747, and mostly, DB00572. These alkaloids are natura...

  9. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.

  10. Drug

    SW033291

    go.drugbank.com/drugs/DB32765
    Experimental

    [A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]